We are live on ! Find out more
AI

Alphabet Inc Portfolio holdings

AUM $4.02B
1-Year Est. Return 215.74%
This Fund
S&P 500
This Quarter Est. Return
-6.67%
1 Year Est. Return
+215.74%
3 Year Est. Return
+350.01%
5 Year Est. Return
+242.03%
10 Year Est. Return
+998.87%
AUM
$1.97B
AUM Growth
-$540M
Cap. Flow
-$210M
Cap. Flow %
-10.65%
Top 10 Hldgs %
88.61%
Holding
44
New
1
Increased
1
Reduced
4
Closed
2

Top Buys

Rank Stock Value
1
TEM
Tempus AI
TEM
+$47.6M
2
RVMD icon
Revolution Medicines
RVMD
+$208K

Top Sells

Rank Stock Value
1
CRWD icon
CrowdStrike
CRWD
+$142M
2
DXCM icon
DexCom
DXCM
+$95.3M
3
IVVD icon
Invivyd
IVVD
+$20.1M
4
ILMN icon
Illumina
ILMN
+$168K
5
MOND
Mondee Holdings, Inc. Class A Common Stock
MOND
+$42.5K

Sector Composition

Rank Sector Weight
1 Technology 65.24%
2 Healthcare 31.4%
3 Industrials 3.24%
4 Consumer Staples 0.12%
5 Consumer Discretionary 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GUTS icon
26
Fractyl Health
GUTS
$123M
$2.83M 0.14%
662,584
– –
AUTL
27
Autolus Therapeutics
AUTL
$386M
$2.43M 0.12%
698,262
– –
BHIL
28
DELISTED
Benson Hill, Inc.
BHIL
$2.3M 0.12%
438,636
– –
BRNS
29
Barinthus Biotherapeutics
BRNS
$24.6M
$2.12M 0.11%
1,513,644
– –
KRON
30
DELISTED
Kronos Bio
KRON
$1.78M 0.09%
1,438,232
– –
RANI icon
31
Rani Therapeutics
RANI
$95.6M
$1.7M 0.09%
448,492
– –
RAPT
32
DELISTED
RAPT Therapeutics
RAPT
$1.65M 0.08%
67,534
– –
TSHA icon
33
Taysha Gene Therapies
TSHA
$1.59B
$1.44M 0.07%
640,882
– –
SPRO icon
34
Spero Therapeutics
SPRO
$68.9M
$1.16M 0.06%
889,979
– –
EXAS
35
DELISTED
Exact Sciences
EXAS
$980K 0.05%
23,205
– –
ALEC icon
36
Alector
ALEC
$164M
$798K 0.04%
175,866
– –
HYPR icon
37
Hyperfine
HYPR
$94.7M
$764K 0.04%
898,720
– –
QNCX icon
38
Quince Therapeutics
QNCX
$17.5M
$142K 0.01%
946
– –
FULC icon
39
Fulcrum Therapeutics
FULC
$248M
$88.4K ﹤0.01%
14,262
– –
RGEN icon
40
Repligen
RGEN
$7.44B
$48.3K ﹤0.01%
383
– –
IVVD icon
41
Invivyd
IVVD
$180M
– –
-4,527,122
Closed -$20.1M
MOND
42
DELISTED
Mondee Holdings, Inc. Class A Common Stock
MOND
– –
-18,420
Closed -$42.5K
HLTH
43
DELISTED
Cue Health Inc. Common Stock
HLTH
$0 ﹤0.01%
27,000
– –
NVTA
44
DELISTED
Invitae Corporation
NVTA
$0 ﹤0.01%
235,606
– –
1
2

Similar funds

JSW
Journey Strategic Wealth Summit, New Jersey $4.03B AUM 33.12% 1-Year Est. Return
BWA
Brave Warrior Advisors New York $4.04B AUM 1.15% 1-Year Est. Return
MAM
Martingale Asset Management Boston, Massachusetts $3.99B AUM 22.65% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
USCWA
U.S. Capital Wealth Advisors Austin, Texas $3.98B AUM 22.36% 1-Year Est. Return
ICP
Ilex Capital Partners London, United Kingdom $4.06B AUM 6.11% 1-Year Est. Return
CA
CSM Advisors Warrendale, Pennsylvania $4.07B AUM 29.62% 1-Year Est. Return
MGP
Metis Global Partners San Diego, California $4.07B AUM 30.82% 1-Year Est. Return

Alphabet Inc's Q2 2024 Portfolio in Review

As of Q2 2024, Alphabet Inc held 44 positions worth $1.97B, down 21% from $2.51B the previous quarter. Its ten largest holdings account for 89% of the portfolio.

Alphabet Inc withdrew a net $210M in Q2 2024, closing 2 positions and reducing 4 holdings. Its most notable exit was Invivyd, an estimated $20.1M position sold in full.

By sector, the portfolio is most concentrated in Technology at 65% of assets, up from 62% a quarter earlier, followed by Healthcare and Industrials.

Against the trend, Alphabet Inc opened a new position in Tempus AI worth $54.3M.

  • Alphabet Inc's largest Q2 2024 buy was Tempus AI: 1,551,102 shares worth $54.3M.
  • Alphabet Inc added most to Revolution Medicines in Q2 2024, an estimated $208K increase.
  • Alphabet Inc's biggest Q2 2024 reduction was CrowdStrike, cutting an estimated $142M.
  • Alphabet Inc fully exited Invivyd in Q2 2024, selling an estimated $20.1M.
  • Alphabet Inc's ten largest holdings make up 89% of its $1.97B portfolio in Q2 2024.
  • Alphabet Inc opened 1 new position and closed 2 in Q2 2024.
  • Alphabet Inc's portfolio value fell 21% quarter-over-quarter to $1.97B.

Based on Alphabet Inc's 13F filing for Q2 2024, filed 2 Aug 2024.